||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Summit Corp Share Discussion Threads
Showing 38326 to 38350 of 38350 messages
|Just out on twitter
We're hiring! View open positions & find out more about joining our team advancing txs in #Duchenne & #Cdiff hTTp://www.summitplc.com/about/careers/
Shows Summit on the move again reflects Glyn's earlier positive presentation.|
|I think we ticked it up, vatnabrekk :-)|
|Good to hear they have term sheets on the table re RDZ and whichever route they go, confirmed it will be non dilutive.|
|Summit Therapeutics plc (SMMT) Charges Ahead 10.41%, Just After Opening Bell on March 22 to Bolster Health Care Stocks
|Hope it doesn't go too high until I get my top-up in the morning!|
|This evening sounded positive to me & we may get some news on C-Diff this summer if they can agree a non partnership deal with Government type funding.
Edit: Based on NASDAQ close some people must also have thought there were some upbeat comments today - close $12.95 at 1.25 $ to £ = £2.07.
In addition high level of transactions - looking good maybe some upturn on AIM Thursday.|
|High volume in US. Reached the average daily trading volume (3 month average I reckon)in the first half hour.|
|Well not at $13.6 in the US now|
|We're suffering from what seems to be a general market wobble both here and in the USA re: Trump.|
|Quick question of topic anyone here know or have anything to do with MELAS ie. a new research/testing that's happening as the Internet is pretty threadbare of anything to do with it
|Thanks football for your post.
I found recording of Glyn very interesting & a better understanding of why we are where we are with C-Diff.
Good introduction for new investors.
Edit: Registration for Wednesday set up per link below:
|Boardroom Talk: Summit Therapeutics' long road to drug approval
Summit Therapeutics(SUMM) is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.
anyone subscrbe here?|
|Re: NASDAQ - in addition our AIM share price at 207p is much the same as NASDAQ close ... so no reason for an share price hike here.|
|Thanks Waterloo, that's what I remember reading too and I wonder if timing has been made specific as to when first dose of F6 is /was administered?
With the absorption being so vastly improved in F6, am hoping the market is aware that so long as some small "principle" is detectable in F3 trials, F6 results should then follow on with vastly enhanced improvement.
i.e. It would surely be a smart move if some "F6 first patients dosed" RNS is made explaining all this. I wonder if the first dosing of F6 has happened yet?|
|I really would take care with the Nasdaq closing price as it was marked up on very low volume on the last trade.
Re F6 dosing I seem to remember, but happy to be corrected, that they are dosing both F3 and F6 at the same time, although F3 was started earlier and with more kids, so F3 likely to make up the majority of the initial results.|
|pick up where we left off Monday with the charts..onwards and upwards then..gla lth's|
|Summit Therapeutics PLC (ADR)
NASDAQ: SMMT - Mar 17, 4:00 PM EDT
13.21USDPrice increase1.11 (9.17%)|
|Does anyone have an ETA re: F6 dosing and initial results? I know we're due to hear of progress with F3 Q2/3 but I've been wondering how soon that might happen with F6?|
|Indeed the Marathon/PTC scenario is a total scandal .. how on earth can a company act so shamelessly?|
Rightly being slatted especially for calling it disease modifying, which it is not. Welcome to the new world of alternative truth.|
Summit Therapeutics plc Summit Therapeutics To Present At The Oppenheimer 27th Annual Healthcare Conference
Oxford, UK, 15 March 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM), the drug discovery and development company advancing therapies
for Duchenne muscular dystrophy and Clostridium difficile infection,
announces that Mr Glyn Edwards, Chief Executive Officer, will present at
the Oppenheimer 27(th) Annual Healthcare Conference, 22 March 2017 at
2:10pm EDT in New York City.
A live audio webcast of the presentation will be available through the
Investors section on the Company's website, www.summitplc.com. A replay
of the webcast will be available soon after the live presentation
|It's made a good effort today though H.M.
The charts showing any investor where we're heading,past all dma's
onwards and upwards.
looking at the yanks side,a few cents rise on their T trades and they have to sell by the looks of things....gla|
|Did expect a bit of movement today after weekend posts|
|Great stuff... timing couldn't be better ... finger's crossed for a new golden period in american pharmaceuticals. GLA|